J.Jpn. Surg. Soc.. 80(12): 1420-1423, 1979
Report on the annual meeting
IMMUNOTHERAPY OF CANCER PATIENTS WITH BACILLUS CALMETTE-GUERIN: SUMMARY OF SEVEN YEARS OF EXPERIENCE IN JAPAN
|
M. Torisu, K. Iwasaki, M. Katano, H. Fujiwara, H. Yamamoto, M. Nishimura |
The pilot study of this series, seven out of 98 patients (7%) survive for as long as 79 months (mean survival 81.8 months) after initiation of this therapy.
We also carried out randomized study of 155 patients with late stage of gastric cancer. Seventy six in BCG treated group and 79 in the control group. In the BCG treated group, a significant improvement of disease free interval and per cent survival was noted.
From our 7 years of experience with BCG immunotherapy in various cancer patients have indicated that this treatment is significantly beneficial to many patients with late stage cancer, for whom no other effective treatment is available.
To read the PDF file you will need Adobe Reader installed on your computer.